Key Details
Price
$4.21Annual ROE
-40.18%Beta
2.19Events Calendar
Next earnings date:
Feb 21, 2025Recent quarterly earnings:
Nov 6, 2024Recent annual earnings:
Feb 22, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
Relay Therapeutics (RLAY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Relay Therapeutics (RLAY) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
The heavy selling pressure might have exhausted for Relay Therapeutics (RLAY) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Relay Therapeutics (RLAY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
The biotech firmed up the details of its upcoming secondary share issue. However, the flotation will be dilutive to existing shareholders.
CAMBRIDGE, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, announced today the pricing of an underwritten public offering of 28,571,429 shares of its common stock at a public offering price of $7.00 per share.
RLAY stock soars on positive interim efficacy data from the early-stage study of its doublet therapy, RLY-2608 in combination with Faslodex, for treating MBC.
CAMBRIDGE, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, announced today that it has commenced an underwritten public offering of $200 million of shares of its common stock.
U.S. stocks traded higher toward the end of trading, with the S&P 500 gaining around 1% on Monday.
3 new programs include 2 genetic disease programs – vascular malformations & Fabry disease – & 1 precision oncology program – NRAS-specific inhibitor Cash guidance remains unchanged, and is expected to fund operations into second half of 2026 Relay Therapeutics to host webcast event today, June 6, at 8:00 a.m. ET CAMBRIDGE, Mass.
FAQ
- What is the ticker symbol for Relay Therapeutics?
- Does Relay Therapeutics pay dividends?
- What sector is Relay Therapeutics in?
- What industry is Relay Therapeutics in?
- What country is Relay Therapeutics based in?
- When did Relay Therapeutics go public?
- Is Relay Therapeutics in the S&P 500?
- Is Relay Therapeutics in the NASDAQ 100?
- Is Relay Therapeutics in the Dow Jones?
- When was Relay Therapeutics's last earnings report?
- When does Relay Therapeutics report earnings?
- Should I buy Relay Therapeutics stock now?